These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1076 related articles for article (PubMed ID: 15726516)

  • 21. The role of saliva in oral health: strategies for prevention and management of xerostomia.
    Brosky ME
    J Support Oncol; 2007 May; 5(5):215-25. PubMed ID: 17564151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
    Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
    Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
    Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer.
    Chao KS
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):20-5. PubMed ID: 11917280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target delineation.
    Braaksma M; Levendag P
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):63-70. PubMed ID: 12577248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial.
    Wasserman TH; Brizel DM; Henke M; Monnier A; Eschwege F; Sauer R; Strnad V
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):985-90. PubMed ID: 16253773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer.
    Jellema AP; Slotman BJ; Muller MJ; Leemans CR; Smeele LE; Hoekman K; Aaronson NK; Langendijk JA
    Cancer; 2006 Aug; 107(3):544-53. PubMed ID: 16804929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Importance of the initial volume of parotid glands in xerostomia for patients with head and neck cancers treated with IMRT.
    Nishimura Y; Nakamatsu K; Shibata T; Kanamori S; Koike R; Okumura M; Suzuki M
    Jpn J Clin Oncol; 2005 Jul; 35(7):375-9. PubMed ID: 15976068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amifostine--a radioprotector in locally advanced head and neck tumors.
    Schönekäs KG; Wagner W; Prott FJ
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():27-9. PubMed ID: 10584137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on the radioprotective potency of amifostine on salivary glands of rats during fractionated irradiation: acute and late effects.
    Sagowski C; Wenzel S; Metternich FU; Kehrl W
    Eur Arch Otorhinolaryngol; 2003 Jan; 260(1):42-7. PubMed ID: 12520356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intensity-modulated radiation therapy and xerostomia.
    Chambers MS; Weber RS; Garden AS
    J Calif Dent Assoc; 2006 Sep; 34(9):743-8. PubMed ID: 17022299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation.
    Rodrigues NA; Killion L; Hickey G; Silver B; Martin C; Stevenson MA; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1079-83. PubMed ID: 19327910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel dose constraint to reduce xerostomia in head-and-neck cancer patients treated with intensity-modulated radiotherapy.
    Strigari L; Benassi M; Arcangeli G; Bruzzaniti V; Giovinazzo G; Marucci L
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):269-76. PubMed ID: 20100642
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation between saliva production and quality of life measurements in head and neck cancer patients treated with intensity-modulated radiotherapy.
    Scrimger R; Kanji A; Parliament M; Warkentin H; Field C; Jha N; Hanson J
    Am J Clin Oncol; 2007 Jun; 30(3):271-7. PubMed ID: 17551304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathophysiology and management of radiation-induced xerostomia.
    Berk LB; Shivnani AT; Small W
    J Support Oncol; 2005; 3(3):191-200. PubMed ID: 15915820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
    Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study.
    Buentzel J; Micke O; Adamietz IA; Monnier A; Glatzel M; de Vries A
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):684-91. PubMed ID: 16243440
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of pilocarpine during radiation therapy: results of RTOG 97-09, a phase III randomized study in head and neck cancer patients.
    Scarantino C; LeVeque F; Swann RS; White R; Schulsinger A; Hodson DI; Meredith R; Foote R; Brachman D; Lee N
    J Support Oncol; 2006 May; 4(5):252-8. PubMed ID: 16724649
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
    Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.